Geron to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation starts on May 24, 2022, at 7 a.m. ET. A webcast will be accessible in the Investor Relations section of Geron's website, with an archive available for 30 days after the event. Geron is advancing its lead candidate, imetelstat, through two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005151/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What date will Geron's presentation at the H.C. Wainwright Global Investment Conference take place?

Geron's presentation will be available on May 24, 2022, starting at 7 a.m. ET.

How can I access the webcast for Geron's presentation?

The webcast can be accessed through the Investor Relations section of Geron's website.

What are the names of the Phase 3 clinical trials Geron is conducting?

Geron is conducting two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

What is Geron's lead drug candidate?

Geron's lead drug candidate is imetelstat, a telomerase inhibitor for treating hematologic malignancies.